NCT04026997

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: CinDome Pharma, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.

Conditions

• Gastroparesis

Interventions

Type	Name	Description
DRUG	CIN-102 Dose 1	CIN-102 Dose 1
DRUG	CIN-102 Dose 2	CIN-102 Dose 2
DRUG	CIN-102 Dose 3	CIN-102 Dose 3
DRUG	Placebo	Placebo

Timeline

• Start date: 2019-09-11
• Primary completion: 2020-12-17
• Completion: 2020-12-17
• First posted: 2019-07-19
• Last updated: 2026-03-25
• Results posted: 2026-03-25

Locations

19 sites across 1 country: United States

Regulatory

• FDA-regulated drug study